Subcutaneous sumatriptan pharmacokinetics: Delimiting the monoamine oxidase inhibitor effect: Research submission

Headache

Volumn 50, Issue 2, 2010, Pages 249-255

  Fox, Anthony W ^a  

^a EBD Group   (United States)

Author keywords

Drug interaction; Monoamine oxidase; Pharmacokinetics; Sumatriptan

Indexed keywords

MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; SUMATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CLUSTER HEADACHE; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; FEMALE; HUMAN; MIGRAINE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

BRAIN; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; INDOLEACETIC ACIDS; MIGRAINE DISORDERS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PHARMACOKINETICS; SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 75849164959     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01568.x     Document Type: Article

References (16)

1. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol. 1994 47: 1253 1257.
2. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol. 1995 47: 543 548.
3. GlaxoSmithKline (2005). C92-050. A study to determine whether the pharmacokinetics, safety or tolerability of subcutaneously administered sumatriptan (6 mg) are altered by interaction with concurrent oral monoamine oxidase inhibitors. http://www.gsk-clinicalstudyregister.com/files/pdf/3184.pdf (Accessed July 8, 2009).
4. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal, and intranasal administration. Eur J Pharm Sci. 1998 6: 99 104.
5. TM: A novel transdermal formulation of sumatriptan. Headache. 2009 49: 817 825.
6. Maas HJ, Spruit AH, Danhof M, Della Pasqual OE. Relevance of absorption rate and lag time to the onset of action in migraine. Clin Pharmacokinet. 2008 47: 139 146.
7. Freidank-Mueschenborn E, Fox AW. Resolution of concentration-response differences in onset of effect between subcutaneous and oral sumatriptan. Headache. 2005 45: 632 637.
8. Tfelt-Hansen P. Parenteral vs, oral sumatriptan and naratriptan: Plasma levels and efficacy in migraine: A comment. J Headache Pain. 2007 8: 273 276.
9. Millson DS, Tepper SJ, Rapoport AM. Migraine pharmacotherapy with oral triptans: A rational approach to clinical management. Expert Opin Pharmacother. 2000 1: 391 404.
10. Diamond S. The use of sumatriptan in patients on monoamine oxidase inhibitors. Neurology. 1995 45: 1039 1040.
11. Freitag FG, Diamond S, Diamond ML, Urban GJ, Pepper BJ. Subcutaneous sumatriptan in patients treated with monoamine oxidase inhibitors and other prophylactic agents. Headache Q. 1998 9: 165 171.
12. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol. 1995 15: 106 108.
13. Putnam GP, O'Quinn SV, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: A large-scale, prospective study. Cephalalgia. 1999 19: 668 675.
14. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart W. Migraine, quality of life, and depression: A population-based case control study. Neurology. 2000 55: 629 635.
15. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescription of triptans with potentially interacting medications: A cohort study involving 240,268 patients. Headache. 2003 43: 44 48.
16. Butcher JC. Numerical Methods for Ordinary Differential Equations, 2nd edn. Chichester: J Wiley & Son 2008: 93 104.